Researchers working on a late-stage trial for an HIV vaccine, said Wednesday they are discontinuing…
By Simon Druker
Jan. 18 (UPI) — Researchers working on a late-stage trial for an HIV vaccine said Wednesday they are discontinuing their work, ending the latest hope for a breakthrough.
The National Institutes of Health confirmed the news of the investigational trial of Mosaico, which began in 2019. It was the only HIV vaccine currently in a late-stage clinical trial.
The vaccine was initially developed by Janssen Vaccines & Prevention, owned by parent Johnson & Johnson. Patients received four injections over a year of the vaccine, which used a cold virus to deliver immunogens.